ARTICLE | Clinical News
Aranesp darbepoetin alfa: Additional Phase III data
September 20, 2010 7:00 AM UTC
Amgen previously reported that Aranesp missed the 2 composite co-primary endpoints of time to all-cause mortality or cardiovascular morbidity and time to all-cause mortality or chronic renal replaceme...